Report Overview
Global Plasma Derived Medicine Market size is expected to be worth around US$ 36.6 Billion by 2034 from US$ 16.8 Billion in 2024, growing at a CAGR of 8.1% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 37.2% share with a revenue of US$ 6.2 Billion.
The Global Plasma Derived Medicine Market is experiencing sustained growth due to the increasing demand for life-saving biologic therapies used in the treatment of immune deficiencies, bleeding disorders, neurological conditions, liver diseases, and other chronic illnesses. Plasma-derived medicines, including immunoglobulins, albumin, coagulation factors, and specialized plasma proteins, play a vital role in modern healthcare by providing therapeutic options for patients with complex and rare diseases.
The market generated US$ 16.8 billion in revenue in 2024 and is projected to reach approximately US$ 36.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 8.1% during the forecast period. Growth is supported by the rising prevalence of immunological and hematological disorders, increasing plasma collection activities, advancements in fractionation technologies, and expanding healthcare access worldwide. Greater awareness of rare diseases and continuous investments in biologics manufacturing are also contributing to market expansion.
Among product categories, immunoglobulin dominated the market with a 60.5% share in 2024, reflecting its extensive use in treating primary immunodeficiency and autoimmune disorders. Bleeding disorders represented the largest application segment, accounting for 63.5% of the market. North America held the leading regional position with a 37.2% market share, supported by advanced plasma collection infrastructure, favorable regulatory frameworks, strong healthcare spending, and the presence of major plasma-derived medicine manufacturers.
Click here for more information: https://market.us/report/plasma-derived-medicine-market/
Key Takeaways
- The global Plasma Derived Medicine Market was valued at US$ 16.8 Billion in 2024 and is projected to reach US$ 36.6 Billion by 2034, expanding at a CAGR of 8.1% during the forecast period.
- By product, the market is segmented into immunoglobulin, albumin, coagulation factors, and others, with immunoglobulin dominating the market, accounting for 60.5% of the total share in 2024.
- Based on application, the market is categorized into bleeding disorders, multifocal motor neuropathy, liver disease, and others, with bleeding disorders holding the largest share of 63.5% in 2024.
- North America emerged as the leading regional market, capturing 37.2% of the global market share in 2024 .
Key Market Segments
- By Product
- Immunoglobin
- Albumin
- Coagulation Factors
- Others
- By Application
- Bleeding Disorders
- Multifocal Motor Neuropathy
- Liver Disease
- Others
Market Key Players
- Shanghai RAAS
- Kedrion
- Kameda Pharmaceuticals
- Grifols
- CSL Limited
- Biotest AG
- Bio Products Laboratory
- ADMA Biologics
Market Dynamics
Driver
The growing prevalence of primary immunodeficiency disorders (PIDs), autoimmune diseases, neurological disorders, and bleeding disorders is a major driver of the plasma derived medicine market. Plasma-derived therapies, including immunoglobulins, albumin, and coagulation factors, are essential for patients whose conditions cannot be effectively managed with conventional medicines. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 3.6 million people in the United States are living with hepatitis C, many of whom may develop advanced liver disease requiring albumin therapy.
The National Institutes of Health (NIH) estimates that primary immunodeficiency diseases affect approximately 1 in 1,200 people, while the World Federation of Hemophilia (WFH) reported that over 427,000 people worldwide are identified with bleeding disorders, including hemophilia and von Willebrand disease. Growing awareness, earlier diagnosis, and improved access to specialized healthcare have increased the use of plasma-derived medicines globally. Additionally, aging populations and rising demand for life-saving biologics continue to accelerate plasma collection, fractionation capacity, and therapeutic adoption across hospitals and specialty treatment centers.
Trend
A prominent trend in the plasma derived medicine market is the expansion of plasma collection infrastructure and the adoption of advanced fractionation technologies to improve production efficiency and product safety. Growing global demand for immunoglobulin therapies has encouraged manufacturers to increase plasma donation centers while implementing enhanced viral inactivation and purification technologies.
According to the U.S. Food and Drug Administration (FDA), plasma-derived medicinal products undergo multiple validated viral reduction and pathogen-removal steps to ensure high safety standards. The Plasma Protein Therapeutics Association (PPTA) reports that manufacturing plasma-derived therapies requires large volumes of human plasma, often collected from hundreds to thousands of qualified donations for a single production batch.
Digital donor management systems, automated plasmapheresis equipment, and stringent quality control protocols are improving collection efficiency and product consistency. Furthermore, ongoing research is expanding the clinical use of immunoglobulins in neurological and autoimmune disorders, while healthcare providers increasingly emphasize personalized treatment strategies. These technological advancements continue to strengthen supply reliability and support broader clinical adoption worldwide.
Restraint
A significant restraint affecting the plasma derived medicine market is the limited availability of human plasma and the highly complex manufacturing process required to produce safe biological therapies. Plasma-derived medicines rely entirely on voluntary or compensated human plasma donations, making production vulnerable to fluctuations in donor participation.
According to the U.S. Food and Drug Administration (FDA), plasma donations must undergo rigorous donor screening, infectious disease testing, and multiple purification processes before therapeutic use. The World Health Organization (WHO) reports that approximately 118.5 million blood donations are collected globally each year, yet plasma availability remains insufficient in many regions due to increasing clinical demand. Fractionation facilities require advanced infrastructure, strict regulatory compliance, and lengthy production cycles that may extend over several months before products reach healthcare providers.
Additionally, transportation, cold-chain storage, and quality assurance significantly increase operational costs. Regulatory inspections and stringent manufacturing standards further lengthen approval timelines. These supply constraints, combined with high production expenses and dependence on donor availability, continue to challenge manufacturers in meeting rising global demand for plasma-derived medicines.
Opportunity
The plasma derived medicine market presents substantial opportunities through expanding therapeutic indications and increasing government support for rare disease diagnosis and treatment. Plasma-derived immunoglobulins and coagulation factors are increasingly used to manage neurological disorders, immune deficiencies, rare genetic diseases, and severe infections.
According to the National Institutes of Health (NIH), approximately 25–30 million Americans are affected by one of more than 7,000 rare diseases, many of which require specialized biological therapies. The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development continues to encourage innovation by supporting therapies for rare disorders through orphan drug incentives and regulatory assistance. Governments worldwide are also investing in national blood collection systems, plasma donation awareness campaigns, and advanced fractionation capabilities to improve treatment accessibility.
Expanding healthcare infrastructure in emerging economies, together with improved reimbursement policies and increasing diagnosis of immune and bleeding disorders, is expected to create new growth opportunities. Continued research into novel plasma proteins and recombinant combinations will further broaden the therapeutic potential of plasma-derived medicines across global healthcare systems.
Conclusion
The global Plasma Derived Medicine Market is set for robust growth, driven by the increasing demand for plasma-based therapies to treat immune deficiencies, bleeding disorders, neurological diseases, and other chronic conditions. With the market projected to grow from US$ 16.8 billion in 2024 to US$ 36.6 billion by 2034, at a CAGR of 8.1%, the industry is expected to benefit from continued advancements in plasma fractionation technologies, expanding plasma collection networks, and rising investments in biologics manufacturing.
The strong market position of immunoglobulin products and the high demand for therapies targeting bleeding disorders underscore the critical role of plasma-derived medicines in modern healthcare. Furthermore, North America's leadership reflects its well-established healthcare infrastructure, advanced regulatory framework, and strong plasma donation ecosystem. As awareness of rare and chronic diseases continues to increase and access to specialized treatments improves worldwide, the plasma derived medicine market is expected to witness sustained expansion, creating significant opportunities for innovation, improved patient outcomes, and long-term growth across the global healthcare sector.
Top comments (0)